27 July 2018 : Clinical Research
Clinical Significance of G Protein-Coupled Receptor 110 (GPR110) as a Novel Prognostic Biomarker in Osteosarcoma
Zhiqiang Liu1B, Guorong Zhang1B, Changlei Zhao1C, Juming Li2A*DOI: 10.12659/MSM.909555
Med Sci Monit 2018; 24: CLR5216-5224
Abstract
BACKGROUND: G protein-coupled receptor 110 (GPR110) belongs to the subfamily of the adhesion G protein-coupled receptors (GPCRs). The potential role of GPR110 has been correlated with cancer cell invasion in some tumors such as glioma. However, its expression and role in human osteosarcoma has not been identified. This study aimed to examine the expression level of GPR110 and determine whether the expression of GPR110 was correlated with aggressive clinicopathological characteristics and prognosis of osteosarcoma.
MATERIAL AND METHODS: This retrospective study included 94 osteosarcoma patients. Immunohistochemistry staining and quantitative real-time polymerase chain reaction were performed to detect the expression level of GPR110 in osteosarcoma specimens. We then determined the correlation of the GPR110 expression with the clinicopathological characteristics and prognosis by univariate or multivariate analysis. Patient outcomes were evaluated using the Kaplan-Meier log-rank test and prognostic factors were detected by multivariate analysis. The function of GPR110 on cell proliferation, migration, and invasion were examined in this in vitro study.
RESULTS: Overexpression of GPR110 was correlated with the advanced stage of osteosarcoma. Patients with high expression level of GPR110 had significantly poorer 5-year overall survival; the multivariate analysis found that GPR110 expression level can act as an independent prognosis factor. Knockdown of GPR110 can decrease the proliferation, migration, and invasion capacity of human osteosarcoma cell lines.
CONCLUSIONS: Our studies suggest a role of GPR110 in tumor progression and as a potential novel prognostic biomarker in osteosarcoma.
Editorial
01 March 2024 : Editorial
Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and Transfusion-Dependent β-ThalassemiaDOI: 10.12659/MSM.944204
Med Sci Monit 2024; 30:e944204
In Press
21 Feb 2024 : Clinical Research
Potential Value of HSP90α in Prognosis of Triple-Negative Breast CancerMed Sci Monit In Press; DOI: 10.12659/MSM.943049
22 Feb 2024 : Review article
Differentiation of Native Vertebral Osteomyelitis: A Comprehensive Review of Imaging Techniques and Future ...Med Sci Monit In Press; DOI: 10.12659/MSM.943168
23 Feb 2024 : Clinical Research
A Study of 60 Patients with Low Back Pain to Compare Outcomes Following Magnetotherapy, Ultrasound, Laser, ...Med Sci Monit In Press; DOI: 10.12659/MSM.943732
26 Feb 2024 : Clinical Research
Predictive Value of Combined HbA1c and Neutrophil-to-Lymphocyte Ratio for Diabetic Peripheral Neuropathy in...Med Sci Monit In Press; DOI: 10.12659/MSM.942509
Most Viewed Current Articles
17 Jan 2024 : Review article
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
16 May 2023 : Clinical Research
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
14 Dec 2022 : Clinical Research
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
01 Jan 2022 : Editorial
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...DOI :10.12659/MSM.935952
Med Sci Monit 2022; 28:e935952